NO3014707T3 - - Google Patents

Info

Publication number
NO3014707T3
NO3014707T3 NO15745380A NO15745380A NO3014707T3 NO 3014707 T3 NO3014707 T3 NO 3014707T3 NO 15745380 A NO15745380 A NO 15745380A NO 15745380 A NO15745380 A NO 15745380A NO 3014707 T3 NO3014707 T3 NO 3014707T3
Authority
NO
Norway
Application number
NO15745380A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO3014707T3 publication Critical patent/NO3014707T3/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO15745380A 2013-12-26 2015-06-23 NO3014707T3 (cg-RX-API-DMAC10.html)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361920819P 2013-12-26 2013-12-26

Publications (1)

Publication Number Publication Date
NO3014707T3 true NO3014707T3 (cg-RX-API-DMAC10.html) 2018-01-06

Family

ID=52293273

Family Applications (1)

Application Number Title Priority Date Filing Date
NO15745380A NO3014707T3 (cg-RX-API-DMAC10.html) 2013-12-26 2015-06-23

Country Status (22)

Country Link
US (2) US9914731B2 (cg-RX-API-DMAC10.html)
EP (2) EP3087070B1 (cg-RX-API-DMAC10.html)
JP (1) JP2017500362A (cg-RX-API-DMAC10.html)
KR (1) KR20160110390A (cg-RX-API-DMAC10.html)
CN (1) CN106029661B (cg-RX-API-DMAC10.html)
AU (1) AU2014370186A1 (cg-RX-API-DMAC10.html)
BR (1) BR112016015057A2 (cg-RX-API-DMAC10.html)
CA (1) CA2934667A1 (cg-RX-API-DMAC10.html)
CL (1) CL2016001604A1 (cg-RX-API-DMAC10.html)
DK (1) DK3087070T3 (cg-RX-API-DMAC10.html)
EA (2) EA201890061A3 (cg-RX-API-DMAC10.html)
ES (1) ES2654931T3 (cg-RX-API-DMAC10.html)
HU (1) HUE037579T2 (cg-RX-API-DMAC10.html)
IL (1) IL246311A0 (cg-RX-API-DMAC10.html)
MX (1) MX2016008445A (cg-RX-API-DMAC10.html)
NO (1) NO3014707T3 (cg-RX-API-DMAC10.html)
PH (1) PH12016501232A1 (cg-RX-API-DMAC10.html)
PL (1) PL3087070T3 (cg-RX-API-DMAC10.html)
PT (1) PT3087070T (cg-RX-API-DMAC10.html)
SG (1) SG11201605207PA (cg-RX-API-DMAC10.html)
SI (1) SI3087070T1 (cg-RX-API-DMAC10.html)
WO (1) WO2015100117A1 (cg-RX-API-DMAC10.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2992586A1 (en) * 2015-07-16 2017-01-19 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
CN106467541B (zh) * 2015-08-18 2019-04-05 暨南大学 取代喹诺酮类衍生物或其药学上可接受的盐或立体异构体及其药用组合物和应用
CN106543145B (zh) * 2016-10-28 2019-07-19 山西医科大学 c-Met激酶抑剂3-(4-氟苯基)嘧啶酮-5-甲酸酰胺衍生物、制备方法与应用
JP7193460B2 (ja) * 2016-12-23 2022-12-20 プレキシコン インコーポレーテッド Cdk8調節およびその適応症のための化合物および方法
JP6888101B2 (ja) 2017-01-18 2021-06-16 アレイ バイオファーマ インコーポレイテッド RETキナーゼ阻害剤としての置換ピラゾロ[1,5−a]ピラジン化合物
CN111372925B (zh) * 2017-11-24 2022-09-02 南京明德新药研发有限公司 作为c-MET/AXL抑制剂的尿嘧啶类化合物
CN111630054B (zh) 2018-01-18 2023-05-09 奥瑞生物药品公司 作为RET激酶抑制剂的取代的吡唑并[3,4-d]嘧啶化合物
EP3740486A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
EP3740491A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
PT3842425T (pt) * 2018-08-24 2024-07-02 Transthera Sciences Nanjing Inc Novo inibidor derivado de quinolina
UY38349A (es) * 2018-08-30 2020-03-31 Array Biopharma Inc Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met
ES2922314T3 (es) 2018-09-10 2022-09-13 Array Biopharma Inc Compuestos heterocíclicos condensados como inhibidores de cinasa RET
CA3129665A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
CN110467616B (zh) * 2019-07-01 2021-12-21 江西科技师范大学 含杂芳基取代哒嗪酮结构的三唑并吡嗪类化合物的制备及应用
CN110330479A (zh) * 2019-07-19 2019-10-15 南京华威医药科技集团有限公司 一种用作axl抑制剂的抗肿瘤化合物及其用途
WO2021043217A1 (zh) * 2019-09-06 2021-03-11 中国科学院上海药物研究所 具有Axl与c-Met激酶抑制活性的化合物及其制备和应用
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
IL296790B1 (en) 2020-03-30 2026-07-01 Hutchmed Ltd Amide compounds and their uses
WO2023286719A1 (ja) * 2021-07-13 2023-01-19 日本曹達株式会社 ウラシル化合物の製造方法
IT202100022682A1 (it) * 2021-09-01 2023-03-01 Luigi Frati Derivati pirimidinici e loro uso nel trattamento di tumori
CN116655626B (zh) * 2023-05-24 2025-03-11 遵义医科大学 一种含咪唑并[l,2-a]吡啶骨架的环丙二酰胺化合物及其制备方法和用途
CN122270275A (zh) * 2023-08-07 2026-06-23 科景特生物科学公司 用于fgfr抑制的化合物
WO2025111224A1 (en) * 2023-11-21 2025-05-30 Fmc Corporation Linked bicyclic compounds for controlling and combating invertebrate pests

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020506A1 (es) * 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
US20050288290A1 (en) * 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors
US7547782B2 (en) * 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
US7723330B2 (en) * 2006-03-07 2010-05-25 Array Biopharma Inc. Heterobicyclic pyrazole compounds and methods of use
KR20090090336A (ko) * 2006-12-12 2009-08-25 다케다 야쿠힌 고교 가부시키가이샤 융합된 헤테로시클릭 화합물
EP1972628A1 (en) 2007-03-21 2008-09-24 Schwarz Pharma Ag Indolizines and aza-analog derivatives thereof as CNS active compounds
CA2732520A1 (en) 2008-08-05 2010-02-11 Merck Sharp & Dohme Corp. Therapeutic compounds
PT3511330T (pt) * 2009-12-31 2020-12-24 Hutchison Medipharma Ltd Intermediário sintético útil na preparação de inibidores de triazolopiridina c-met
BR112013021638A2 (pt) * 2011-02-25 2016-08-02 Irm Llc "compostos inibidores de trk, seu uso e composições que os compreendem"
CN102827186A (zh) * 2011-06-16 2012-12-19 中国科学院上海药物研究所 一类吡啶并五元杂环衍生物及其制备方法和用途
US9283225B2 (en) * 2011-08-10 2016-03-15 Merck Patent Gmbh Pyrido-pyrimidine derivatives
AU2012312515A1 (en) * 2011-09-19 2014-03-13 Genentech, Inc. Combination treatments comprising c-met antagonists and B-raf antagonists
EA023521B1 (ru) * 2011-11-14 2016-06-30 Сефалон, Инк. ПРОИЗВОДНЫЕ УРАЦИЛА В КАЧЕСТВЕ ИНГИБИТОРОВ AXL И c-MET КИНАЗЫ
WO2013180949A1 (en) * 2012-05-27 2013-12-05 Ning Xi Substituted quinoline compounds and methods of use

Also Published As

Publication number Publication date
SG11201605207PA (en) 2016-07-28
AU2014370186A1 (en) 2016-07-14
US9914731B2 (en) 2018-03-13
IL246311A0 (en) 2016-08-02
PH12016501232A1 (en) 2016-08-15
EA201890061A2 (ru) 2018-05-31
BR112016015057A2 (pt) 2017-08-08
SI3087070T1 (en) 2018-01-31
EA201691164A1 (ru) 2016-12-30
HUE037579T2 (hu) 2018-09-28
US20160318929A1 (en) 2016-11-03
EA029757B1 (ru) 2018-05-31
CN106029661B (zh) 2017-11-03
PL3087070T3 (pl) 2018-03-30
CN106029661A (zh) 2016-10-12
JP2017500362A (ja) 2017-01-05
CL2016001604A1 (es) 2017-05-26
KR20160110390A (ko) 2016-09-21
PT3087070T (pt) 2018-01-30
WO2015100117A1 (en) 2015-07-02
EP3309160A1 (en) 2018-04-18
MX2016008445A (es) 2016-10-28
ES2654931T3 (es) 2018-02-15
US20180148447A1 (en) 2018-05-31
EP3087070B1 (en) 2017-11-08
CA2934667A1 (en) 2015-07-02
DK3087070T3 (en) 2017-12-04
EP3087070A1 (en) 2016-11-02
AU2014370186A2 (en) 2016-07-21
EA201890061A3 (ru) 2018-09-28

Similar Documents

Publication Publication Date Title
AP2016009275A0 (cg-RX-API-DMAC10.html)
BR112016004195A2 (cg-RX-API-DMAC10.html)
BR112015007533A2 (cg-RX-API-DMAC10.html)
BR112014017733A2 (cg-RX-API-DMAC10.html)
BR112014017739A2 (cg-RX-API-DMAC10.html)
BR112014019326A2 (cg-RX-API-DMAC10.html)
BR112014018502A2 (cg-RX-API-DMAC10.html)
BR112016003412A2 (cg-RX-API-DMAC10.html)
BR112014018516A2 (cg-RX-API-DMAC10.html)
BR112014017765A2 (cg-RX-API-DMAC10.html)
BR112014018480A2 (cg-RX-API-DMAC10.html)
BR112014020341A2 (cg-RX-API-DMAC10.html)
BR112016005446A2 (cg-RX-API-DMAC10.html)
BR112015026369A2 (cg-RX-API-DMAC10.html)
BR112014021878A2 (cg-RX-API-DMAC10.html)
BR112014018468A2 (cg-RX-API-DMAC10.html)
BR112016012903A2 (cg-RX-API-DMAC10.html)
BR112014018207A2 (cg-RX-API-DMAC10.html)
BR112014019204A2 (cg-RX-API-DMAC10.html)
BR112014017901A2 (cg-RX-API-DMAC10.html)
BR112014017745A2 (cg-RX-API-DMAC10.html)
BR112016004357A2 (cg-RX-API-DMAC10.html)
BR112014017722A2 (cg-RX-API-DMAC10.html)
BR112014017653A2 (cg-RX-API-DMAC10.html)
BR112014018578A2 (cg-RX-API-DMAC10.html)